PsiOxus Therapeutics Ltd. news
- Key data from the first-in-human FORTITUDE trial shows that a single cycle of intravenous (IV) NG-350A drives dose-dependent increases in specific inflammatory biomarkers, consistent with the mechanism of the encoded anti- CD40 agonist.
- IV dosing of NG-350A led to elevations in IL-12, IFNγ and IL-17 that were higher and sustained for longer than those reported for systemic CD40 agonists.
- NG-350A monotherapy was well-tolerated and dose exploration will continue
- Single IV cycle of PsiOxus’ T-SIGn vector enabled an otherwise non-effective dose of CAR-T cell therapy to clear primary and metastatic tumors in vivo
- Reprogramming of the tumor microenvironment using T-SIGn vectors could enable a variety of CAR-T therapies to overcome limitations in solid tumors
- Data is currently being presented at the AACR Virtual Annual Meeting 2021
OXFORD, UK & CAMBRIDGE, Mass./USA – 14 April 2
OXFORD, UK – 7 April 2021: PsiOxus Therapeutics, Ltd. (PsiOxus) today announced an updated agreement to advance its clinical collaboration with Bristol Myers Squibb (NYSE: BMY) to evaluate the safety, tolerability, and preliminary efficacy of PsiOxus’ tumor re-engineering platform, in combination with Bristol Myers Squibb’s PD-1 immune checkpoint inhibitor Opdivo® (nivolumab) to treat a range of tumor types in late-stage cancer patients.
March 05, 2020 – OXFORD, UK – PsiOxus® Therapeutics, Ltd. (PsiOxus), the gene therapy for cancer company, today announced that it has started a clinical trial with NG-641, a four transgene tumor-microenvironment modifying cancer gene therapy. This is the first time that a tumor- specific virus containing four different therapeutic transgenes has been administered to cancer patients.
PsiOxus also announced today th